| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 319119 | European Neuropsychopharmacology | 2008 | 22 Pages |
This study characterized the novel neurokinin (NK)1 antagonist, vestipitant, under clinical evaluation for treatment of anxiety and depression. Vestipitant possessed high affinity for human NK1 receptors (pKi, 9.4), and potently blocked Substance P-mediated phosphorylation of Extracellular-Regulated-Kinase. In vivo, it occupied central NK1 receptors in gerbils (Inhibitory Dose50, 0.11 mg/kg). At similar doses, it abrogated nociception elicited by formalin in gerbils, and blocked foot-tapping and locomotion elicited by the NK1 agonist, GR73632, in gerbils and guinea pigs, respectively. Further, vestipitant attenuated fear-induced foot-tapping in gerbils, separation-induced distress-vocalizations in guinea pigs, marble-burying behaviour in mice, and displayed anxiolytic actions in Vogel conflict and fear-induced ultrasonic vocalization procedures in rats. These actions were mimicked by CP99,994, L733,060 and GR205,171 which acted stereoselectively vs its less active isomer, GR226,206. In conclusion, vestipitant is a potent NK1 receptor antagonist: its actions support the utility of NK1 receptor blockade in the alleviation of anxiety and, possibly, depression.
